Add The Health Site as a
Preferred Source
Add The Health Site as a Preferred Source

Low libido, fall in testosterone levels seen in COVID-19 positive men

While scientists have said that low testosterone levels could be a cause for COVID-19 complications, a new study finds that this virus may also deplete testosterone.

Low libido, fall in testosterone levels seen in COVID-19 positive men
Low testosterone is also associated with infection-related hospitalisation and all-cause mortality in male in ICU patients, so testosterone treatment may also have benefits beyond improving outcomes for COVID-19.

Written by Jahnavi Sarma |Updated : September 30, 2020 9:11 AM IST

Since the beginning of the current global health crisis, scientists have said that the COVID-19 virus affects men more severely than women. This virus also has the habit of being unpredictable in the sense that it has kept the scientific community on its toes with its various complications and manifestations. The elderly and those with underlying health conditions are at risk of severe complications and the risk of transmission is high. Even asymptomatic people can contribute to the spread of the virus.

Now, in a major study on patients hospitalised due to COVID-19, the researchers from the University of Mersin in Turkey found that the disease might deteriorate men's testosterone levels. The findings, published in the journal The Aging Male, revealed that, as men's testosterone level at baseline decreases, the probability for them to be in the intensive care unit (ICU) significantly increases. While it has already been reported that low testosterone levels could be a cause for poor prognosis following a positive SARS-CoV-2 test, this is the first study to show that COVID-19 itself depletes testosterone. "Testosterone is associated with the immune system of respiratory organs, and low levels of testosterone might increase the risk of respiratory infections.

Testosterone treatment may improve COVID-19 outcome in men

Low testosterone is also associated with infection-related hospitalisation and all-cause mortality in male in ICU patients, so testosterone treatment may also have benefits beyond improving outcomes for COVID-19. The research team looked at a total of 438 patients. This included 232 males, each with laboratory-confirmed SARS-CoV-2. All data were prospectively collected. A detailed clinical history, complete physical examination, laboratory and radiological imaging studies were performed in every patient. All data of the patients were checked and reviewed by the two physicians. The cohort study was divided into three groups: asymptomatic patients (46), symptomatic patients who were hospitalized in the internal medicine unit (IMU) (29), and patients who were hospitalized in the intensive care unit (ICU) (46).

Also Read

More News

Testosterone levels fall as severity of infection increases

In this study, the mean total testosterone decreased, as the severity of the COVID-19 increased. The mean total testosterone level was significantly lower in the ICU group than in the asymptomatic group. In addition, the mean total testosterone level was significantly lower in the ICU group than in the Intermediate Care Unit group. The mean serum follicle-stimulating hormone level was significantly higher in the ICU group than in the asymptomatic group.

Even asymptomatic male patients experience loss of libido

Researchers found Hypogonadism - a condition in which the body doesn't produce enough testosterone in -- (51.1 per cent) -- of the male patients. The patients who died had significantly lower mean total testosterone than the patients who were alive. However, even 65.2 per cent of the 46 male patients who were asymptomatic had a loss of libido. The authors state future studies should look at the concentration levels of ACE2 (Angiotensin-converting enzyme 2) -- an enzyme attached to the cell membranes of cells located in the intestines -- in relationship with the total testosterone levels.

Add The HealthSite as a Preferred Source Add The Health Site as a Preferred Source

(With inputs from IANS)